- Aromatic amine derivative organic electroluminescent material and device thereof
-
The invention discloses an aromatic amine derivative organic electroluminescent material and a device thereof. The compound is a pyrene compound substituted with an aromatic amine, wherein the compound has a substituted or unsubstituted (hetero) aryl group and a pyrene compound substituted or unsubstituted aromatic amine structure of a (hetero) aryl group, which may be used as a light emitting material in an organic electroluminescent device. These novel compounds can provide better device performance, such as higher external quantum efficiency and narrower half-peak widths, and the like.
- -
-
Paragraph 0311-0315
(2021/11/26)
-
- INFLUENZA VIRUS REPLICATION INHIBITOR AND USES THEREOF
-
The invention belongs to the field of medicine, and particularly relates to a novel compound as a replication inhibitor of influenza virus and a preparation method thereof, a pharmaceutical composition comprising the compound and use of the compound and pharmaceutical composition thereof in treating influenza. The present invention provides a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, The compound of the present invention can inhibit influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties.
- -
-
Paragraph 00190; 00317-00318
(2020/05/21)
-
- SHMT INHIBITORS AND USES THEREOF
-
The present invention provides compounds, compositions thereof, and methods of using the same.
- -
-
Paragraph 00232
(2018/06/30)
-
- NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II
-
The invention relates novel NK1 receptor antagonists represented in formula A, wherein R1 and R2 independently are selected from the group consisting of (C1-4)alkyl, (C1-4)haloalkyl, (C1-4)alkoxy, CD
- -
-
Page/Page column 110
(2015/03/13)
-
- FUSED HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS
-
Fused heterocyclic compounds useful for prevention, treatment or improvement of diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R1 is an aryl group fused to a saturated ring or the like, A, B, L1, R2, L2, L3, Y, L4, R3 and X are defined in the description), a tautomer, prodrug or a pharmaceutically acceptable salt of the compound or a solvate thereof.
- -
-
Page/Page column 32
(2012/08/28)
-
- SUBSTITUTED PARA-BIPHENYLOXYMETHYL DIHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF
-
The present invention relates to a series of substituted para-biphenyloxymethyl dihydro oxazolopyrimidinones of formula (I) as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of
- -
-
Page/Page column 44
(2011/04/19)
-
- Anti-cancer agents and uses thereof
-
The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.
- -
-
Page/Page column 27
(2008/12/08)
-
- Anti-cancer agents and uses thereof
-
The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.
- -
-
Page/Page column 27
(2008/06/13)
-
- A simple and improved procedure for selective ring bromination of alkyl-substituted aromatic hydrocarbons on the surface of alumina
-
Highly selective ring bromination of alkyl-substituted aromatic hydrocarbons has been achieved using molecular bromine adsorbed on the surface of alumina without any solvent.
- Ranu,Sarkar,Chakraborty
-
p. 1095 - 1099
(2007/10/02)
-
- Intermediate Formation ofMetacyclophane on Flash Vacuum Thermolysis
-
Pyrolysis of 2,6-tetramethylene Dewar benzene (2a) under flash vacuum thermolysis (FVT) conditions at 400 deg C gave 6- and 5-methylindan (8a (2.5percent) and 10a (2.5percent), respectively) as well tetralin (5a) (45percent).These products indicate that metacyclophane (1a) was formed in the gas phase, but it decomposed under the reaction conditions either via homolytic cleavage of one of the benzylic bonds to yield a diradical (6a) leading to 8a and 10a or it gave 5a via benzvalene intermediate (4a).Deuterium labeling supports the proposed mechanism.A very similar course of events was observed on FVT of metacyclophane at 600 deg C; it yielded methyl-substituted tetralins (8c, 10c) as the sole products.The analogies and differences in the behavior of the two metacyclophanes are discussed.
- Kostermans, Gerardus, B. M.,Dansik, Paul van,Wolf, Willem H. de,Bickelhaupt, Friedrich
-
p. 4531 - 4534
(2007/10/02)
-
- Hydrocarbures arylaliphatiques. Partie VII. Orientation dans la reaction de bromation de benzocyclenes bi- et tricycliques superieurs
-
The bromination of 1,2,3-trimethylbenzene, and bi- and tricyclic fused ring systems (i.e. indan, tetralin, benzosuberan, 2a,3,4,5-tetrahydroacenaphthen and higher homologues) is described in this paper.This work is part of a research project studying the ring size influence of peri-fused semi-aromatic ring system on benzene reactivity.This study was started in a first step on acetylation and was continued on bromination.Forthcoming studies (now underway) concern the kinetic measurement of protodesilylation of univocal silyl derivatives.The synthesis of the starting bromo derivatives used for this latter study is described here.These bromides were used for the attribution via NMR spectroscopy of the electrophile reaction site in the direct bromination of the fused ring unsymmetrical systems (the reactive sites are obvious in symmetrical molecules). Thus, meta substitution is predominant in the case of tetraline and benzosuberan, but ortho substitution is relatively more important in tetralin.In 1,2,3-trimethylbenzene and the fused tricyclic compounds, substitution takes place in an ortho position respective to the substituent or the ring system, the meta position being totally deactivated.In the special case of a five-membered ring, the ortho position this ring is always non reactive.The reactivity differences between these compounds are explained by hyper conjugation and the stabilities of the transition states.
- Gruber, Rene,Cagniant, Denise,Cagniant, Paul
-
-
